Related Experiment Video
Updated: May 10, 2026
08:31
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Summary
Silodosin effectively treats benign prostatic hyperplasia symptoms, offering uroselectivity and convenient once-daily dosing. Clinical trials confirm its efficacy and safety, with minimal cardiovascular effects and manageable side effects like retrograde ejaculation.
Area of Science:
- Pharmacology
- Urology
Context:
- Benign prostatic hyperplasia (BPH) affects a significant number of aging men.
- Alpha1A-adrenoceptor antagonists are a cornerstone of BPH pharmacotherapy.
- Existing treatments may have limitations in efficacy or side effect profiles.
Purpose:
- To evaluate the efficacy and safety of silodosin for treating lower urinary tract symptoms (LUTS) associated with BPH.
- To compare silodosin's effectiveness against placebo and tamsulosin.
Summary:
- Silodosin, a selective alpha1A-adrenoceptor antagonist, demonstrated significant improvement in International Prostate Symptom Score (IPSS) total, storage, and voiding subscores compared to placebo (p < 0.001).
- It was found to be at least as effective as tamsulosin (0.4 mg QD) and superior in simultaneously improving specific bothersome LUTS like incomplete emptying, frequency, and nocturia (p = 0.03).
- Phase 3 trials involving over 800 patients showed silodosin (8 mg QD) is well-tolerated, with minimal cardiovascular effects and a manageable rate of retrograde ejaculation (3.9% discontinuation).
Impact:
- Silodosin offers a valuable therapeutic option for BPH management with advantages in uroselectivity and dosing convenience.
- Its favorable safety profile, including minimal cardiovascular impact, allows for concomitant use with other medications.
- Patient education regarding potential side effects like intraocular floppy iris syndrome is crucial for safe and effective treatment.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...